Update on the management of advanced breast cancer Journal Article
| Authors: | Fornier, M.; Munster, P.; Seidman, A. D.; Winer, E. P.; Matulonis, U.; Blum, J. L. |
| Article Title: | Update on the management of advanced breast cancer |
| Abstract: | Recent trials comparing single-agent vs combination therapy in metastatic breast cancer suggest that it may be time to reconsider the belief that combination chemotherapy is the gold standard of treatment. Based on the limited randomized trial data available to date, high-dose chemotherapy with stem-cell rescue should not be viewed as 'state-of-the-art' treatment for metastatic disease and should be used only in the context of clinical trials. Recent trials have explored the optimal dosing and scheduling of the taxanes, as well as the possible role of these agents in combination regimens. Capecitabine (Xeloda), a new oral fluoropyrimidine, appears to be comparable in efficacy to CMF (cyclophosphamide, methotrexate, and fluorouracil), and preclinical data suggest possible synergy between this agent and the taxanes. Other promising agents under study include liposome-encapsulated doxorubicin (TLCD-99), an immunoconjugate linking a chimeric human/mouse monoclonal antibody to doxorubicin molecules; MTA (LY231514), a multitargeted antifolate; and marimistat, a broad-spectrum matrix metalloproteinase inhibitor. Tamoxifen (Nolvadex) remains the most important hormonal agent, but new antiestrogens and selective estrogen receptor modulators (SERMs) may provide alternatives. The potential role of new aromatase inhibitors as first-line hormonal agents requires further study. Finally, the possible synergy between trastuzumab (Herceptin), a recombinant humanized monoclonal antibody to the HER-2/neu protein, and paclitaxel (Taxol) is being studied in two clinical trials. |
| Keywords: | cancer chemotherapy; cancer survival; treatment outcome; unclassified drug; review; doxorubicin; cancer combination chemotherapy; antineoplastic agents; capecitabine; paclitaxel; antineoplastic agent; unindexed drug; cancer immunotherapy; breast cancer; bone marrow suppression; mucosa inflammation; neuropathy; antineoplastic combined chemotherapy protocols; aromatase inhibitor; hematopoietic stem cell transplantation; breast neoplasms; docetaxel; exemestane; monoclonal antibody; antibodies, monoclonal; recombinant antibody; thromboembolism; neoplasm metastasis; letrozole; alitretinoin; aminoglutethimide; mifepristone; taxane derivative; trastuzumab; anastrozole; pemetrexed; clinical trials; biological products; drug induced disease; antiestrogen; megestrol acetate; toremifene; oral drug administration; raloxifene; oncogene neu; selective estrogen receptor modulator; tamoxifen citrate; humans; human; female; formestane; vorozole; antigestagen; fadrozole; idoxifene; losoxantrone |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 13 |
| Issue: | 5 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 1999-05-01 |
| Start Page: | 647 |
| End Page: | 664 |
| Language: | English |
| PUBMED: | 10356685 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 16 August 2016 -- Source: Scopus |
Citation Impact
Related MSK Work